Review is not the same as debate, which is the word I deliberately used in the prior post. Please point to a case where a P&T committee has ever rejected the use of an FDA-approved substitutable generic.
It is not a problem for MNTA if SNY retains a substantial part of the sales. Sandoz taking 40-60% of sales is a smashing success. Taking more than that in a duopoly would produce worse bottom line results.
Market Data 
Markets 
AI
